FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series C

Biotech startups that raised Series C

Updated 9 Nov 2026

Biotech startups that raised Series C
$29
one-time
  • 700 funded companies, 572 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 15 columns
  • Download right after payment
Download right after paymentFree 25-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 25-row sample first. No account, no payment.

startups-biotech--series-c.csv700 rows × 15 columns
CompanyCityLast roundAmountDate
MicrobioticaCambridgeSeries C$47.9M2026-10-16
BigHat BiosciencesSan MateoSeries C$75.0M2026-09-24
Basecamp ResearchLondonSeries C$140.0M2026-09-23
QL BiopharmaBeijingSeries C$44.7M2026-09-14
ImmunoPhotonicsSt LouisSeries C$10.1M2026-09-01
AusperBioHangzhouSeries C$120.0M2026-08-27
Bridge to LifeNorthbrookSeries C$110.0M2026-08-12
Ratio TherapeuticsBostonSeries C$70.0M2026-07-31

8 rows of the CSV in 5 of its 15 columns.

700
Startups
$55.2B
Total raised
72
Funded in the last 12 months
$4.4B
Raised in the last 12 months

Source: FundingWatcher. Data as of 9 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 700
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Microbiotica Microbiotica develops live bacterial microbiome therapeutics and associated biomarkers. Biotech Cambridge Series C $47.9M 2026-10-16 $130.7M Seventure Partners, IP Group, Cambridge Innovation Capital +1 11 to 50 2016
BigHat Biosciences BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. Artificial intelligence San Mateo Series C $75.0M 2026-09-24 $174.3M Andreessen Horowitz, Gaingels, 8VC +2 51 to 100 2019
Basecamp Research Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. Artificial intelligence London Series C $140.0M 2026-09-23 $219.9M True Ventures, redalpine, Hummingbird Ventures +1 51 to 100 2019
QL Biopharma QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. Biotech Beijing Series C $44.7M 2026-09-14 $173.7M Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 101 to 250 2018
ImmunoPhotonics ImmunoPhotonics is a biotechnology company that develops cancer immunotherapies to stimulate immune responses against tumors. Biotech St Louis Series C $10.1M 2026-09-01 $42.0M TCA Venture Group, Cultivation Capital, Arch Grants +1 11 to 50 2012
AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
Bridge to Life Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. Biotech Northbrook Series C $110.0M 2026-08-12 $167.5M Perceptive Advisors 101 to 250 2005
Ratio Therapeutics Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. Biotech Boston Series C $70.0M 2026-07-31 $160.0M Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments 11 to 50 2021
Diyingjia Technology Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. Artificial intelligence Beijing Series C $3.0M 2026-07-28 $32.3M IDG Capital, Legend Capital, Microsoft Accelerator 11 to 50 2017
Shengqiang Technology Shengqiang Technology researches, manufactures, and sells high-tech products. Biotech Shenzhen Series C $13.7M 2026-07-26 $13.7M SDIC Venture Capital 101 to 250 2013
Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017
Chai Discovery Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. Artificial intelligence San Francisco Series C $400.0M 2026-07-14 $631.0M Thrive Capital, OpenAI 11 to 50 2024
Automata Automata provides laboratory automation software and hardware to increase efficiency in scientific workflows. Artificial intelligence London Series C $45.0M 2026-06-25 $144.8M Octopus Ventures, Firstminute Capital, Hummingbird Ventures +1 101 to 250 2015
Cellanome Cellanome uses synthetic biology and informatics methods to analyze multi-omics data. Biotech Redwood City Series C $75.9M 2026-06-18 $289.6M Premji Invest, Synetro Group 51 to 100 2020
Triveni Bio Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. Biotech Watertown Series C $65.0M 2026-06-17 $272.0M Polaris Partners, OrbiMed, Alexandria Venture Investments +2 11 to 50 2019
CereVasc CereVasc develops a minimally invasive treatment for communicating hydrocephalus. Biotech Charlestown Series C $85.0M 2026-06-04 $199.0M Perceptive Advisors, Bain Capital Life Sciences, ATON Partners 11 to 50 2014
Weikaier Pharmaceutical Technology Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. Biotech Nanjing Series C $29.6M 2026-06-02 $120.4M SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 501 to 1,000 2010
YolTech Therapeutics YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. Biotech Minhang Series C $73.8M 2026-05-29 $144.9M K2VC, UnityVC, Decheng Capital +1 11 to 50 2021
Cerevance Cerevance develops novel therapeutics for neurological diseases. Biotech Boston Series C $20.0M 2026-05-12 $209.5M Google Ventures, Casdin Capital, Foresite Capital +1 51 to 100 2016
Terremoto Biosciences Terremoto Biosciences develops medicines using lysine-based covalent chemistry. Biotech San Francisco Series C $108.0M 2026-04-15 $358.0M OrbiMed, Novo Holdings, Third Rock Ventures +2 51 to 100 2021
ADCendo ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. Biotech Copenhagen Series C $75.0M 2026-04-14 $324.6M RA Capital Management, Novo Holdings, Gilde Healthcare +2 51 to 100 2017
Terrestrial Bio Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. Biotech Cambridge Series C $50.0M 2026-03-26 $180.9M RA Capital Management, National Institutes of Health, The Engine 11 to 50 2012
Cognito Therapeutics Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. Biotech Cambridge Series C $105.0M 2026-03-05 $321.8M Morningside, FoundersX Ventures, IAG Capital Partners +1 11 to 50 2016
Brainomix Brainomix creates AI-powered imaging biomarkers that support precision medicine treatment decisions. Artificial intelligence Oxford Series C $6.5M 2026-02-24 $60.2M Innovate UK, Parkwalk Advisors, Boehringer Ingelheim Venture Fund +1 51 to 100 2010
Loyal Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. Biotech San Francisco Series C $100.0M 2026-02-11 $237.1M Khosla Ventures, First Round Capital, Quiet Capital +1 101 to 250 2019
Colossal Biosciences Unicorn Colossal Biosciences uses gene editing technology to pursue de-extinction of species. Biotech Austin Series C $60.0M 2026-02-03 $628.1M Boost VC, Capital Factory, Climate Capital 101 to 250 2021
Nuclera Nuclera provides a protein prototyping system that makes proteins readily available to drug discovery researchers. Biotech Cambridge Series C $12.0M 2026-01-13 $157.8M Innovate UK, Verve Ventures, Amadeus Capital Partners +2 101 to 250 2013
Zenitar Zenitar conducts drug research and biomedical technology industrialization. Biotech Chengdu Series C $86.0M 2026-01-12 $155.7M Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital 51 to 100 2019
bit.bio Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. Biotech Cambridge Series C $50.0M 2026-01-09 $225.0M Metaplanet, Foresite Capital 101 to 250 2016
Beacon Therapeutics Beacon Therapeutics develops treatments to preserve and restore vision for eye diseases. Biotech Alachua Series C $75.0M 2026-01-08 $365.1M Oxford Science Enterprises, Forbion Capital Partners, Advent Life Sciences +1 101 to 250 2023

Table 1. Biotech startups that raised Series C: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 9 November 2026. Base: 700.

Largest rounds

Last 12 months
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 Chai Discovery Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. Artificial intelligence San Francisco Series C $400.0M 2026-07-14 $631.0M Thrive Capital, OpenAI 11 to 50 2024
2 Basecamp Research Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. Artificial intelligence London Series C $140.0M 2026-09-23 $219.9M True Ventures, redalpine, Hummingbird Ventures +1 51 to 100 2019
3 AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
4 Aspen Neuroscience Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. Biotech San Diego Series C $115.0M 2025-11-20 $387.0M Google Ventures, OrbiMed, EDBI +2 101 to 250 2018
5 DP Technology DP Technology applies AI to scientific research and industrial R&D challenges worldwide. Artificial intelligence Haidian Series C $113.9M 2025-12-24 $253.7M Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 101 to 250 2018
6 Bridge to Life Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. Biotech Northbrook Series C $110.0M 2026-08-12 $167.5M Perceptive Advisors 101 to 250 2005
7 Terremoto Biosciences Terremoto Biosciences develops medicines using lysine-based covalent chemistry. Biotech San Francisco Series C $108.0M 2026-04-15 $358.0M OrbiMed, Novo Holdings, Third Rock Ventures +2 51 to 100 2021
8 Cognito Therapeutics Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. Biotech Cambridge Series C $105.0M 2026-03-05 $321.8M Morningside, FoundersX Ventures, IAG Capital Partners +1 11 to 50 2016
9 Loyal Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. Biotech San Francisco Series C $100.0M 2026-02-11 $237.1M Khosla Ventures, First Round Capital, Quiet Capital +1 101 to 250 2019
10 Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017

Table 2. Biotech startups that raised Series C: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 9 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 OrbiMed Private equity firm new-york-new-york 12 2% 3 Triveni Bio, Terremoto Biosciences, Aspen Neuroscience
2 RA Capital Management Startup incubator Boston 11 2% 2 ADCendo, Terrestrial Bio
3 Bristol-Myers Squibb Venture capital firm new-york-new-york 8 1% 2 BigHat Biosciences, Ratio Therapeutics
4 Khosla Ventures Venture capital firm Menlo Park 7 1% 2 Prellis Biologics, Loyal
5 National Science Foundation Entrepreneurship program Alexandria 7 1% 1 Culture Biosciences
6 KfW Government investment office Frankfurt 7 1%
7 Novo Holdings Corporate venture arm Hellerup 6 1% 2 Terremoto Biosciences, ADCendo
8 Alexandria Venture Investments Venture capital firm Pasadena 5 1% 2 Triveni Bio, Aspen Neuroscience
9 Cormorant Asset Management Hedge fund Boston 5 1% 1 Triveni Bio
10 Invus Private equity firm new-york-new-york 5 1% 1 Triveni Bio
11 Decheng Capital Venture capital firm Menlo Park 5 1% 1 YolTech Therapeutics
12 Y Combinator Startup accelerator Mountain View 5 1% 1 Culture Biosciences
13 HTGF (High-Tech Gruenderfonds) Venture capital firm Bonn 5 1%
14 Temasek Private equity firm Singapore 5 1%
15 Alumni Ventures Angel group Manchester 5 1%

Table 3. Biotech startups that raised Series C: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 9 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 621 89% $50.8B
Software 67 10% $8.0B
Artificial intelligence 36 5% $5.4B
Hardware 27 4% $2.0B
Fintech 7 1% $543.0M
Energy 6 1% $245.8M
Education 2 0% $81.2M
Cybersecurity 1 0%

Table 4. Biotech startups that raised Series C by sector. Source: FundingWatcher. Data as of 9 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series C 700 100% $28.5M

Table 5. Biotech startups that raised Series C by stage of the most recent round. Source: FundingWatcher. Data as of 9 November 2026.

Countries

CountriesCompaniesShare
United States 337 48%
China 160 23%
United Kingdom 39 6%
South Korea 34 5%
Switzerland 20 3%
Japan 15 2%
Germany 15 2%
Israel 15 2%
Canada 12 2%
France 11 2%
Denmark 5 1%
The Netherlands 5 1%

Table 6. Biotech startups that raised Series C by headquarters country. Source: FundingWatcher. Data as of 9 November 2026.

Cities

CitiesCompaniesShare
Shanghai 29 4%
San Francisco 26 4%
San Diego 26 4%
Cambridge 22 3%
Hangzhou 20 3%
Beijing 19 3%
Nanjing 15 2%
Boston 13 2%
Seoul 13 2%
Menlo Park 12 2%
Guangzhou 12 2%
London 10 1%

Table 7. Biotech startups that raised Series C by headquarters city. Source: FundingWatcher. Data as of 9 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
October 2026 4 6% $444.9M
September 2026 6 8% $432.9M
August 2026 4 6% $267.1M
July 2026 13 18% $823.0M
June 2026 8 11% $429.8M
May 2026 5 7% $149.2M
April 2026 5 7% $340.7M
March 2026 7 10% $329.8M
February 2026 5 7% $231.5M
January 2026 6 8% $468.0M
December 2025 5 7% $236.0M
November 2025 4 6% $235.0M

Table 8. Biotech startups that raised Series C: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 9 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 63 9% $3.9B
2025 63 9% $3.4B
2024 71 10% $3.1B
2023 44 6% $1.5B
2022 67 10% $3.3B
2021 81 12% $5.8B

Table 9. Biotech startups that raised Series C by year of the most recent round. Source: FundingWatcher. Data as of 9 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 3 0%
2020 to 2022 24 3%
2015 to 2019 241 35%
2010 to 2014 174 25%
Before 2010 256 37%

Table 10. Biotech startups that raised Series C by founding year. Source: FundingWatcher. Data as of 9 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 77 11%
11 to 50 297 43%
51 to 100 145 21%
101 to 250 97 14%
251 to 500 29 4%
501 to 1,000 24 4%
1,001 to 5,000 10 1%
5,001 to 10,000 2 0%
10,001 or more 3 0%

Table 11. Biotech startups that raised Series C by headcount. Source: FundingWatcher. Data as of 9 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups that raised Series C are on the list?
700, in the file dated 9 November 2026. 72 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 15 columns: name, website, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 700 rows, no account. Every investor and every startup, two files, cost $299.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 25 rows.
How current is the data?
The file is dated 9 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series C: 700 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, website, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

Not sure about the data?

Download a free 25-row sample first. No account, no payment.

Biotech at other stages

Other sectors that raised Series C

Cite: FundingWatcher, 700 biotech companies whose most recent round is Series C, 9 November 2026. https://fundingwatcher.com/startups/biotech/series-c/